Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro

Andrea E Wahner Hendrickson, Paul Haluska, Paula A. Schneider, David A. Loegering, Kevin L. Peterson, Ricardo Attar, B. Douglas Smith, Charles Erlichman, Marco Gottardis, Judith E. Karp, Joan M. Carboni, Scott H Kaufmann

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia. In the present study, immunoblotting and reverse transcription-PCR demonstrated expression of IGF1R and IR isoform A in acute myelogenous leukemia (AML) cell lines as well as in >80% of clinical AML isolates. Treatment with insulin enhanced signaling through the Akt and MEK1/2 pathways as well as survival of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor phosphorylation as well as downstream signaling through MEK1/2 and Akt. These changes inhibited proliferation and, in some AML cell lines, induced apoptosis at submicromolar concentrations. Likewise, BMS-536924 inhibited leukemic colony formation in CD34+ clinical AML samples in vitro. Collectively, these results not only indicate that expression of IGF1R and IR isoform A is common in AML but also show that interruption of signaling from these receptors inhibits proliferation in clinical AML isolates. Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted.

Original languageEnglish (US)
Pages (from-to)7635-7643
Number of pages9
JournalCancer Research
Volume69
Issue number19
DOIs
StatePublished - Oct 1 2009

Fingerprint

Somatomedin Receptors
Insulin Receptor
Acute Myeloid Leukemia
Protein Isoforms
Cell Line
In Vitro Techniques
BMS 536924
Receptor Protein-Tyrosine Kinases
Immunoblotting
Reverse Transcription
Phosphotransferases
Epithelium
Phosphorylation
Insulin
Apoptosis
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia : Effect of the dual-receptor inhibitor BMS-536924 in vitro. / Wahner Hendrickson, Andrea E; Haluska, Paul; Schneider, Paula A.; Loegering, David A.; Peterson, Kevin L.; Attar, Ricardo; Smith, B. Douglas; Erlichman, Charles; Gottardis, Marco; Karp, Judith E.; Carboni, Joan M.; Kaufmann, Scott H.

In: Cancer Research, Vol. 69, No. 19, 01.10.2009, p. 7635-7643.

Research output: Contribution to journalArticle

Wahner Hendrickson, Andrea E ; Haluska, Paul ; Schneider, Paula A. ; Loegering, David A. ; Peterson, Kevin L. ; Attar, Ricardo ; Smith, B. Douglas ; Erlichman, Charles ; Gottardis, Marco ; Karp, Judith E. ; Carboni, Joan M. ; Kaufmann, Scott H. / Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia : Effect of the dual-receptor inhibitor BMS-536924 in vitro. In: Cancer Research. 2009 ; Vol. 69, No. 19. pp. 7635-7643.
@article{11052e2fde624fb7956361476b3fd9dc,
title = "Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro",
abstract = "The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia. In the present study, immunoblotting and reverse transcription-PCR demonstrated expression of IGF1R and IR isoform A in acute myelogenous leukemia (AML) cell lines as well as in >80{\%} of clinical AML isolates. Treatment with insulin enhanced signaling through the Akt and MEK1/2 pathways as well as survival of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor phosphorylation as well as downstream signaling through MEK1/2 and Akt. These changes inhibited proliferation and, in some AML cell lines, induced apoptosis at submicromolar concentrations. Likewise, BMS-536924 inhibited leukemic colony formation in CD34+ clinical AML samples in vitro. Collectively, these results not only indicate that expression of IGF1R and IR isoform A is common in AML but also show that interruption of signaling from these receptors inhibits proliferation in clinical AML isolates. Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted.",
author = "{Wahner Hendrickson}, {Andrea E} and Paul Haluska and Schneider, {Paula A.} and Loegering, {David A.} and Peterson, {Kevin L.} and Ricardo Attar and Smith, {B. Douglas} and Charles Erlichman and Marco Gottardis and Karp, {Judith E.} and Carboni, {Joan M.} and Kaufmann, {Scott H}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-09-0511",
language = "English (US)",
volume = "69",
pages = "7635--7643",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia

T2 - Effect of the dual-receptor inhibitor BMS-536924 in vitro

AU - Wahner Hendrickson, Andrea E

AU - Haluska, Paul

AU - Schneider, Paula A.

AU - Loegering, David A.

AU - Peterson, Kevin L.

AU - Attar, Ricardo

AU - Smith, B. Douglas

AU - Erlichman, Charles

AU - Gottardis, Marco

AU - Karp, Judith E.

AU - Carboni, Joan M.

AU - Kaufmann, Scott H

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia. In the present study, immunoblotting and reverse transcription-PCR demonstrated expression of IGF1R and IR isoform A in acute myelogenous leukemia (AML) cell lines as well as in >80% of clinical AML isolates. Treatment with insulin enhanced signaling through the Akt and MEK1/2 pathways as well as survival of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor phosphorylation as well as downstream signaling through MEK1/2 and Akt. These changes inhibited proliferation and, in some AML cell lines, induced apoptosis at submicromolar concentrations. Likewise, BMS-536924 inhibited leukemic colony formation in CD34+ clinical AML samples in vitro. Collectively, these results not only indicate that expression of IGF1R and IR isoform A is common in AML but also show that interruption of signaling from these receptors inhibits proliferation in clinical AML isolates. Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted.

AB - The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia. In the present study, immunoblotting and reverse transcription-PCR demonstrated expression of IGF1R and IR isoform A in acute myelogenous leukemia (AML) cell lines as well as in >80% of clinical AML isolates. Treatment with insulin enhanced signaling through the Akt and MEK1/2 pathways as well as survival of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor phosphorylation as well as downstream signaling through MEK1/2 and Akt. These changes inhibited proliferation and, in some AML cell lines, induced apoptosis at submicromolar concentrations. Likewise, BMS-536924 inhibited leukemic colony formation in CD34+ clinical AML samples in vitro. Collectively, these results not only indicate that expression of IGF1R and IR isoform A is common in AML but also show that interruption of signaling from these receptors inhibits proliferation in clinical AML isolates. Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted.

UR - http://www.scopus.com/inward/record.url?scp=70350214534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350214534&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-0511

DO - 10.1158/0008-5472.CAN-09-0511

M3 - Article

C2 - 19789352

AN - SCOPUS:70350214534

VL - 69

SP - 7635

EP - 7643

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -